



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

13 August 2015

DEPARTMENT PERSONNEL ORDER

No. 2015 - 3759

SUBJECT: Reconstitution of the Formulary Executive Council (FEC) for the Philippine National Formulary System (PNFS)

The Formulary Executive Council (FEC) is the duly authorized body that operationalizes the PNFS and recommends to the Secretary of Health the medicines that shall be (a) included into or deleted from the Philippine National Formulary (PNF) and (b) exempted from the Executive Order No. 49 based on the evidence of their efficacy, safety and comparative cost-effectiveness.

The following shall comprise the FEC as members:

1. Froilan Bagabaldo, RPh, LLB
2. Cleotilde How, MD
3. Cecilia Jimeno, MD
4. Hilton Y. Lam, PhD
5. Cecile Maramba-Lazarte, MD
6. Paul Matthew Pasco, MD
7. Imelda G. Peña, DrPH
8. John Wong, MD

Atty. Froilan Bagabaldo, being a consultant of the Pharmaceutical Division (PD), shall be a non-voting member.

INSTITUTIONAL PARTNERS:

- A) Food and Drug Administration (FDA)
- B) Philippine Health Insurance Corporation (Philhealth)
- C) Disease Prevention and Control Bureau (DPCB)


All FEC members shall have a term of three (3) years. The Pharmaceutical Division through its Policy, Planning, Program Development and Research Unit (PPPDRU) shall provide

secretariat support to the FEC. The Council shall meet once a month on a schedule that shall be set based on the availability of the members to ensure the presence of a quorum.

A Chairperson appointed by the Secretary of Health shall serve for a period not exceeding three (3) years with a monthly honorarium of **FIFTEEN THOUSAND PESOS (Php 15,000.00)**.

The regular members of FEC are entitled to collect **TEN THOUSAND PESOS (Php 10,000.00)** per month as honoraria for actual services rendered as reflected in their output and attendance every meeting. However, Atty. Froilan Bagabaldo, shall not be entitled to honoraria since he is engaged as a consultant by the PD. Other government personnel shall likewise not be entitled to honoraria but their participation in the FEC shall be added as intervening points in their Performance Evaluation Scheme (PES).

Under this Order, all expenses incurred by the FEC and honoraria in the conduct of its function shall be charged against the funds of the National Pharmaceutical Policy Development including provision of drugs and medicines, medical and dental supplies to make affordable quality drugs available, General Appropriations Act for Fiscal Year (FY) 2015, subject to the usual accounting and auditing rules and regulations.


JANETTE LORETO-GARIN, MD, MBA-H
Secretary of Health